0000899243-22-025333.txt : 20220706 0000899243-22-025333.hdr.sgml : 20220706 20220706161515 ACCESSION NUMBER: 0000899243-22-025333 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220701 FILED AS OF DATE: 20220706 DATE AS OF CHANGE: 20220706 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Harding Thomas C. CENTRAL INDEX KEY: 0001834833 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35347 FILM NUMBER: 221068858 MAIL ADDRESS: STREET 1: 5500 FLATIRON PARKWAY, SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Clovis Oncology, Inc. CENTRAL INDEX KEY: 0001466301 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900475355 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-5000 MAIL ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-07-01 0 0001466301 Clovis Oncology, Inc. CLVS 0001834833 Harding Thomas C. C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 BOULDER CO 80301 0 1 0 0 See Remarks Common Stock 2022-07-01 4 M 0 16 A 3241 I By wife Common Stock 2022-07-05 4 S 0 7 2.71 D 3234 I By wife Common Stock 14720 D Restricted Stock Units 2022-07-01 4 M 0 16 0.00 D Common Stock 16 124 I By wife Each Restricted Stock Unit represents the right to receive one share of Common Stock. Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. On July 1, 2020, the reporting person's wife was granted 250 Restricted Stock Units. 25% of such Restricted Stock Units vested on July 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Senior Vice President and Chief Scientific Officer /s/ Thomas Harding 2022-07-05